SCHEMBL687971

SCHEMBL687971

CCOc1cccc(-c2ccc([C@H](CC(=O)O)NC(=O)Nc3c(O)ccn(Cc4ccccc4Cl)c3=O)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.42
PTGER3 P43115 8/20 0.40
SLC16A3 O15427 1/20 0.39
SLC16A1 P53985 1/20 0.39
MCTS1 Q9ULC4 1/20 0.39
CYP1A2 P05177 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
ICMT O60725 1/20 0.36
ITGB1 P05556 2/20 0.36
ITGA4 P13612 2/20 0.36
CTSA P10619 1/20 0.36
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687654 0.93 PTGER3 (0.43) PTGER3CYP1A2ITGB1ITGA4
SCHEMBL688158 0.91 RXFP1 (0.45) PTGER3CYP1A2NPSR1RXFP1ITGB1
SCHEMBL687129 0.89 PTGER3 (0.46) PTGER3CYP1A2ITGB1ITGA4CTSA
SCHEMBL687324 0.89 PTGER3 (0.41) PTGER3SLC16A3SLC16A1CYP1A2NPSR1
SCHEMBL687629 0.88 SMN1; SMN2 (0.45) PTGER3CYP1A2NPSR1ITGB1ITGA4
SCHEMBL687251 0.87 PTGER3 (0.42) PTGER3CYP1A2RXFP1
SCHEMBL687906 0.86 PTGER3 (0.47) PTGER3ITGB1ITGA4CTSA
SCHEMBL688165 0.86 PTGER3 (0.41) PTGER3CYP1A2
SCHEMBL687909 0.86 SMN1; SMN2 (0.49) PTGER3NPSR1ITGB1ITGA4
SCHEMBL687117 0.85 PTGER3 (0.52) PTGER3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed